転移性ホルモン感受性前立腺癌に対する アンドロゲン除去療法とアビラテロン酢酸エステル + 低用量プレドニゾロン療法の当院での初期治療経験 --複合アンドロゲン遮断療法との有効性と安全性の比較検討--
書誌事項
- タイトル別名
-
- Comparison of Abiraterone Acetate Plus Prednisolone and Combined Androgen Blockade in High-risk Metastatic Hormone-Sensitive Prostate Cancer
- テンイセイ ホルモン カンジュセイ ゼンリツセンガン ニ タイスル アンド ロゲン ジョキョ リョウホウ ト アビラテロン サクサン エステル+テイヨウリョウ プレドニゾロン リョウホウ ノ トウ イン デ ノ ショキ チリョウ ケイケン : フクゴウ アンド ロゲン シャダン リョウホウ ト ノ ユウコウセイ ト アンゼンセイ ノ ヒカク ケントウ
この論文をさがす
抄録
Abiraterone acetate plus prednisone/prednisolone (AAP) and androgen deprivation therapy (ADT) was approved for the treatment of high-risk metastatic hormone-sensitive prostate cancer (mHSPC) in Japan in 2018. We investigated 22 patients with mHSPC showing ≥2 of 3 high-risk factors (Gleason score ≥8, ≥3 bone lesions or measurable visceral metastases) who received AAP plus ADT at our hospital between March 2018 and October 2019. We compared outcomes between the propensity-score matched AAP plus ADT group and the combined androgen blockade (CAB) group (19 matched pairs, 38 patients) to evaluate the efficacy and safety of AAP plus ADT. Prostate-specific antigen progression-free survival (PSA-PFS) was significantly longer in the AAP group than in the CAB group (not reached vs 15.1 months, p=0.014). Time to achievement of serum PSA ≤0.2 ng/ml and ≤0.1 ng/ml was shorter in the AAP group than in the CAB group (6.4 months vs not reached, p=0.001 and 11.0 months vs not reached, p=0.004, respectively). Although no significant intergroup difference was observed in the overall survival rates and PSA-PFS2 (PSAPFS on subsequent anticancer therapy) owing to the shorter follow-up in the AAP group, our data suggest that the clinical efficacy of AAP is betterthan that of CAB in patients with mHSPC.
収録刊行物
-
- 泌尿器科紀要
-
泌尿器科紀要 66 (12), 427-432, 2020-12-31
泌尿器科紀要刊行会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390572174804622080
-
- NII論文ID
- 120006951704
-
- NII書誌ID
- AN00208315
-
- HANDLE
- 2433/260985
-
- NDL書誌ID
- 031207050
-
- ISSN
- 00181994
-
- 本文言語コード
- ja
-
- データソース種別
-
- JaLC
- IRDB
- NDL
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用可